FLIBANSERIN - Generic Drug Details

What are the generic sources for flibanserin and what is the scope of patent protection?

Flibanserin is the generic ingredient in one branded drug marketed by Sprout Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Flibanserin has forty-two patent family members in twenty-nine countries.

One supplier is listed for this compound.

Summary for FLIBANSERIN

International Patents:	42
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	20
What excipients (inactive ingredients) are in FLIBANSERIN?	FLIBANSERIN excipients list
DailyMed Link:	FLIBANSERIN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FLIBANSERIN

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FLIBANSERIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Andrew McDonald	Phase 2
Mohit Khera	Phase 2
Sprout Pharmaceuticals, Inc	Phase 2

See all FLIBANSERIN clinical trials

Pharmacology for FLIBANSERIN

Mechanism of Action

P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for FLIBANSERIN

G02CX	Other gynecologicals
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for FLIBANSERIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015		RX	Yes	Yes

Expired US Patents for FLIBANSERIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015
Sprout Pharms	ADDYI	flibanserin	TABLET;ORAL	022526-001	Aug 18, 2015

International Patents for FLIBANSERIN

Country	Patent Number	Title	Estimated Expiration
Slovenia	1446122
European Patent Office	1674102
Yugoslavia	30004
Eurasian Patent Organization	200400481

Market Dynamics and Financial Trajectory for Flibanserin

Last updated: March 4, 2026

What Is Flibanserin and Its Therapeutic Profile?

Flibanserin is a centrally acting drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts as a serotonin receptor modulator, affecting neurotransmitter levels related to sexual desire. Approved in 2015 under the brand name Addyi, Flibanserin faces competition from non-pharmacological therapies and emerging treatments.

Global Market Overview

The global market for female sexual dysfunction (FSD) drugs, forecasted to reach USD 2.5 billion by 2025, includes Flibanserin mainly in North America and Europe. The market growth is driven by increased awareness, changing attitudes toward sexual health, and unmet medical needs.

Region	Market Size (USD Billion, 2022)	CAGR (2019-2025)	Key Factors
North America	1.2	8.2%	Regulatory approval, high awareness
Europe	0.8	7.5%	Growing acceptance, aging population
Asia-Pacific	0.3	12.1%	Rising urbanization, increasing focus on sexual health

Market Drivers

1. Increased Awareness & Diagnosis
   Greater acceptance and recognition of female sexual dysfunction have expanded the patient pool.

2. Approval of Flibanserin
   FDA approval in 2015 provided a first-in-class pharmacological treatment for HSDD, activating market entry.

3. Rising Focus on Women's Health
   Societal shifts and advocacy emphasize addressing women's health issues, fostering expansion opportunities.

Market Barriers

1. Adverse Effects and Safety Concerns
   Risks such as hypotension, syncope, and central nervous system effects limit patient acceptance.

2. Limited Efficacy Perception
   Relative modest benefits compared to placebo affect prescription rates.

3. Regulatory Challenges in Non-U.S. Markets
   Approval in Europe and Asia remains inconsistent; regulatory agencies scrutinize safety data.

4. Market Penetration Hurdles
   Many healthcare providers hesitate to prescribe due to side effect profile and limited data on long-term efficacy.

Competitive Landscape

Competitors	Status	Key Attributes
Addyi (Pfizer)	Approved in 2015	First FDA-approved treatment, marketing efforts focus heavily on women.
Bremelanotide	Under review (PT-141)	Intranasal administration, different mechanism targeting libido.
Non-Pharmacological Options	Lifestyle modifications, therapy	Often preferred due to safety profile.

Revenue Trends & Financial Trajectory

Pfizer reported approximately USD 45 million in global sales of Addyi in 2022, indicating modest market penetration. Growth is projected at a compound annual growth rate (CAGR) of 4-5% through 2025, contingent on:

• Expansion into European and Asian markets.
• Development of next-generation formulations with improved safety and efficacy.
• Increased awareness campaigns.

Key Factors Influencing Future Financial Outcomes

• Regulatory Approvals & Labeling Changes: Expanded labeling could increase patient eligibility.
• Pricing & Reimbursement Policies: Reimbursement rates in major markets will impact adoption.
• Market Penetration Strategies: Direct-to-consumer advertising, physician education, and partnerships with health systems.
• Pipeline Developments: Compounds with better safety profiles could replace or supplement Flibanserin.

Regulatory and Policy Landscape

Region	Status	Notable Notes
United States	Approved (2015)	FDA approved with risk management plan.
Europe	Not approved; under review	EMA withheld approval due to safety concerns.
Japan	Pending approval	Requires additional safety data.

Investment and Commercial Implications

Pharmaceutical companies focusing on FSD face a niche market with constrained growth potential unless new indications, formulations, or broader approvals are achieved. Market expansion depends on overcoming safety concerns and improving perception among physicians and patients.

Summary of Market Dynamics and Financial Outlook

The Flibanserin market remains small relative to broader sexual health markets but has growth potential with increased acceptance, regulatory expansion, and improved formulations. However, safety profiles, modest efficacy, and competitive alternatives constrain rapid growth. Pharma investments carry risks tied to regulatory approvals and market penetration strategies.

---

Key Takeaways

• Flibanserin targets HSDD, primarily in North America, with limited global expansion due to regulatory hurdles.
• Market size is approximately USD 2 billion, with steady but modest growth projections.
• Barriers include safety concerns, limited efficacy, and competition from non-drug therapy.
• Future revenue depends on approval expansions, reimbursement policies, and pipeline developments.
• Commercial success will require strategic marketing, safety improvements, or new indications.

---

FAQs

1. What are the primary safety concerns associated with Flibanserin?
   Hypotension, syncope, CNS effects such as dizziness, fatigue, and sleep disturbances.

2. How does Flibanserin compare with emerging therapies?
   Other therapies, like Bremelanotide, offer different mechanisms and administration routes, with some promising safety profiles.

3. Is Flibanserin approved outside the U.S.?
   No, European and Asian regulators have not approved Flibanserin, citing safety concerns or insufficient data.

4. What are the prospects for market expansion?
   Potential exists if formulations improve safety, if additional indications are developed, or if expanded approvals occur.

5. What strategies could enhance Flibanserin’s market penetration?
   Increasing awareness, physician education, optimizing reimbursement, and developing next-generation formulations.

---

References

[1] U.S. Food and Drug Administration. (2015). FDA approves first drug treatment for women with low sexual desire. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-women-low-sexual-desire